Introduction
Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder, characterized by destruction of α-motor neurons of anterior horn cells, which leads to symmetrical muscle weakness and atrophy. It has an estimated incidence of 1/ 10,000 live births (Panigrahi et al., 2002) , and a carrier frequency of 1/50. Clinically proximal SMA is further divided into four types based on the age of onset and severity of the clinical course. Childhood onset SMAs can be classified into three types (Type I-III) (Biros and Forrest, 1999) . Type I is the most severe form having symptoms of SMA before 6 months. Type II is an intermediate form with onset before the age of 18 months. Type III is a relatively milder, chronic form with onset after the age of 18 months. Type IV SMA is an adult form with onset after 30 years of age with variable severity but normal life span.
By molecular analysis all these forms had been mapped to chromosome 5q11.2-q13.3, suggesting that they are allelic disorders. The region has duplications of a large segment consisting at least four genes, which are present in a telomeric (t) and a centromeric (c) copy; Survival motor neuron gene (SMN1 or SMNt and SMN2 or SMNc), neuronal apoptosis inhibitory protein gene (NAIP and ϕ NAIP) basal transcription factor subunit p44 (BTFp44t and BTFp44c) and a novel protein of unknown function H4F5t and H4F5c (Wirth, 2000) . The SMN locus in 5q region is particularly unstable and prone to large scale deletions (Melki et al., 1994) (Figure 1 ).
Survival motor neuron is the most important gene associated with SMA which has two homologous copies, SMN1 and SMN2. It has been observed that the SMN1 gene is deleted in majority of SMA patients (Wirth, 2000) , but SMN2 is not directly associated with disease because 26% of normal individuals in a populations lack both copies. The failure of SMN2 to fully compensate for loss of SMN1 is due to sequence difference in exon 7 which causes alternative splicing of SMN2 and as a result lower amount of full-length protein is produced. An increase in SMN2 copy number could raise protein levels and modify phenotype. However efforts to demonstrate a correlation between SMN2 copy number and disease severity have produced conflicting results (Velasco et al., 1996; McAndrew et al., 1997; Taylor et al., 1998; Feldkotter et al., 2002; Anhuf et al., 2003) NAIP, a gene located 16.5 Kb downstream of SMN, has also been suggested to be an SMA modifier due to its proximity to SMN, and found to be deleted in 45% of SMA type I patients and in 18% of type II and III SMA patients (Roy et al., 1995) .
Genotype-Phenotype correlation of SMN locus genes in spinal m uscular atrophy patients from India
Deletions in NAIP appear to be associated with increased severity of the disease, although the association is not absolute (Roy et al., 1995; Somerville et al., 1997) .
Using comparative genomics to screen for factor/ gene Scharf et al. (1998) identified a novel transcript, H4F5, which lies closer to SMN1 than any previously identified gene in the region. A multicopy microsatellite marker, C212 is located in the last intron of H4F5 gene and is often present in two copies per chromosome. Due to the inherent instability of SMA locus, C212 copy number varies from 1-3 alleles per chromosome in the normal population. It has been reported that polymorphic locus C212 is deleted in more than 90% of type I SMA patients indicating that H4F5 is also highly deleted in type I SMA, and thus is a candidate phenotypic modifier for SMA. The other dinucleotide repeat C272 (Ag1-CA) is located 463 bp upstream of the putative ATG translation initiation sites of both genes (Burglen et al., 1996) . Due to its close proximity, C272 is considered as a marker for integrity of the 5' end of the SMN gene. Analysis using C272 showed that 50% of type I patients had a heterozygosity deficiency of the marker compared with 6% and 10% of types II and III patients respectively (Burlet et al., 1996) .
Gene deletion studies of 5q region suggest involvement of multiple genes with SMA phenotype (Wirth et al., 1995; Burlet et al., 1996; Rodrigues et al., 1996; Velasco et al., 1996; Scharf et al., 1998) . Till date no data on such a correlation has been reported from India. So the main objective of our study was to establish the genotype-phenotype correlation in Indian patients using the SMN, NAIP genes and C212, C272 markers as well as to find out SMN2 copy number in milder patients.
M aterials and M ethods Subject
The study was carried out in patients belonging to all the four groups of proximal SMA. A total of 50 unrelated SMA patients were included in the study. The patients were selected according to the criteria of International SMA Consortium 1999. Seventeen had type I form of SMA, 7 had type II, 23 had type III, and 3 had type IV SMA.
One hundred healthy age, sex and religion matched individual without any history of neurological disease and normal in neurological examination were included as control to know the status of these genes and marker copies in normal individuals.
M ethods
Five ml blood was collected in EDTA tubes from 50 patients and 100 controls. DNA was extracted from blood by the standard salting out method (Olernp and Zetterqnist, 1992) .
Molecular analysis of SMN gene
Patients were tested for homozygous deletion of exons 7 and 8 of SMN1 gene by a Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method as described previously by Kesari et al., 2003 .
Molecular analysis of NAIP gene
All individuals were also tested for exon 5 deletion of NAIP gene. PCR conditions and primers used to amplify the exon 5 were identical to those of Somerville et al. (1997) . The PCR was started with initial denaturation at 96 o C for 7 min followed by amplification for 30 cycles (94 o C, 60 o C and 72 o C for 1.30 min each) followed by a final extension for 10 min at 72 o C. The PCR products were analysed on 2% agarose gel containing ethidium bromide.
Marker analysis (C212 and C272)
PCR was performed according to Wirth et al. (1995) and Di Donato et al. (1994) respectively with some modifications. The samples were denatured initially at 96 o C for 7 min, followed by amplification for 30 cycles (94 o C for 1 min, 62 o C for 30 s, 65 o C for 2 min) and a final extension for 10 min at 72 o C. For sizing of C212 and C272 alleles, a sequencing ladder of pUC18 plasmid DNA was prepared using γ 32 -P dATP end labelled primer by di-deoxy thermosequenase cycle sequencing kit (USB-Amersham Life Sciences, Cleveland, OH) (Mukherjee et al., 2002) . The PCR products of C212/C272 markers along with pUC18 ladder (sequencing ladder) were run on 6% denaturing polyacrylamide sequencing gel to separate the polymorphic alleles. A nomenclature based on the 
C272 C212
size of PCR product was used for C212 so that alleles 40 and 49 correspond to 214 and 232 bp respectively (Wirth et al., 1995) . The alleles for C272 correspond to the exact size of PCR product (Wirth et al., 1995) . The χ 2 statistics for 2×2 tables were calculated using standard procedures and Cervus (Version 1.0) programme was used to calculate the heterozygosity.
SMN2 Copy number analysis
SMN2 gene copy number analysis was carried out by comparing the levels of exon 7 SMN2 amplified products to those of a two-copy control gene following PCR amplification using MTHHR gene as an internal control. After PCR, densitometry analysis was done to calculate the exact copies of SMN2 gene in individuals.
R esults
Our result showed that SMN1 gene was absent in 11/17 (65%) in type I, 5/7 (71%) in type II, 18/23 (78%) in type III SMA patients. Deletion in exon 5 of NAIP gene was observed in 7/17 (41%) in type I, 1/7(14%) in type II, 6/23 (26%) in type III SMA patients, while it was present in all type IV and controls (Table 1) . NAIP gene deletion was observed only in those individuals who had SMN1 gene deletion. None of type IV SMA patients showed absence of SMN1/SMN2 or NAIP genes.
Fifteen different alleles were observed in the normal individual for C212 marker. At an average controls had 2-3 alleles, and in few individual maximum of 4 alleles were detected, with the observed heterozygosity was 0.871 in 100 unrelated controls (Figure 2) . Allele frequencies were similar to those reported in French, Spanish and Italian population (Melki et al., 1994; Capon et al., 1996) . Alleles 48 (230 bp), 49 (232 bp) and 50 (234 bp) and 53 (240 bp) were frequent in our population (Figure 3 ). Alleles 45 (224 bp), 48 (230 bp), 49 (232 bp) were frequent in patient group. Alleles 45 and 48 showed significant association (P 0.002 and P 0.010 respectively) with the disease. Type I patients showed significant heterozygosity deficiency (defined as the reduction of PCR products) by marker C212 (P 0.001) as majority of (91%) patients had one allele of C212 marker, whereas their parents had 2-3 alleles. Heterozygosity deficiency was not significant in type II (P 0.06) and in type III (P 0.09) in our patient group.
Thirteen different types of alleles with sizes of 106-130 bp were observed in C272 marker. One to three alleles were present with the observed heterozygosity of 0.901 in 100 unrelated controls (Figure 4) . Alleles corresponding to 110 bp, 118 bp and 120 bp were common ( Figure 5 ). Eleven alleles of different sizes were observed in the patient group. In this group, alleles 110 bp, 112 bp, 118 bp and 120 bp were common. The marker C272 analysis also showed a significant heterozygosity deficiency (P 0.001) in type I SMA patients as compared with their parents (Figure 6 ). No discordance was observed between SMA III and normal chromosome from both STR markers. The heterozygosity deficiency has been previously ascribed to the deletion of one or two loci spanned by the polymorphic markers (Melki et al., 1994) .
To determine whether SMN1 deletions in SMA patients extended to the flanking region, SMN1 gene deletion results were combined with those obtained for the multicopy markers and NAIP gene. The combined analysis of all markers showed that a large proportion of type I patients (41%) carried deletions of both SMN1 and NAIP gene. The markers analysis in these patients showed loss of heterozygosity of markers, as compared with type II (14%) and type III (26%) patients. No such loss was observed in type IV patients. These results support the idea that heterozygosity deficiency in type I SMA is mainly due to loss of alleles at these loci.
SMN2 copy number analyses were carried out in eleven patients of whom five patients had type I/II SMA, no homozygous deletion of SMN1 gene was observed in them. SMN2 analysis showed 2 copies of SMN2 gene in each of them. SMN2 copy number analyses were also carried out in six type III patients, and we found that 3-5 copies of SMN2 gene were present in these patients. This increase in copy number of SMN2 gene may be responsible for the less severe form of SMA with late onset of symptoms (Table 2) .
D iscussion
Utilizing genotype data obtained from SMN1, SMN2, and polymorphic markers, we postulate that the extent of deletions in SMA region may play an important role in determining the disease severity in patients. However, the exact molecular nature of these mutant alleles remains unclear (W irth et al., 1995) . Our results provide evidence indicating that deletion in SMN1 is important to cause SMA and SMN2 to modify the disease phenotype. Deletion of polymorphic markers at 5q region may modify the clinical presentation of the disease. We have identified two categories of SMA alleles. 'Severe' SMA alleles have large-scale deletions, which remove the entire coding region of SMN1 gene as well as copies of polymorphic markers (C212/C272). In contrast 'mild' allele harbours apparent deletions of exons 7 and 8 of SMN1 gene while 5' end of SMN1 appears to be intact. Although NAIP has been implicated as a modulator of severity of disease but our results suggests that NAIP may not have a direct role in SMA severity. A reduction of C212 alleles was found in type I patients with SMN1 deletion, implying a deletion of one or two copies of C212 in these individuals. Although a small proportion of the C212 allele reductions could be due to homozygosity at the locus rather than true deletion. C212 allele homozygosity is low as reported by Scharf et al. (1998) ; we are also getting only 12% of homozygosity in normal chromosomes as compared to 91% of homozygosity observed in type I SMA patient. Therefore, we believe that C212 allele reduction in type I patients is due to deletion rather than homozygosity of the marker. In comparison with the high rate of allelic loss in type I SMA, the allelic loss in type II and III SMA is between that of type I and normal chromosomes. The allelic loss of C212 in type I patients indirectly implies a deletion of at least a part of H4F5 gene, as C212 polymorphic locus is located in exon 3b of the gene (Scharf et al., 1998) . Therefore, it appears that H4F5 may be deleted at a higher frequency and nearly as high as SMN1 in type I SMA patients. It has been proposed that H4F5 protein function in snRNP biogenesis, as the gene shows homology to a snRNPinteracting protein that colocalizes with the same proteins as SMN. Such function would be appropriate for an SMA modifier gene and H4F5 deletion may be considered important for modulating disease severity.
Due to its location C272 may serve as a marker for the integrity of 5' end of SMN gene. Most acute type I SMA patients harbour loss of alleles detected by this marker. Although small proportion of allelic reduction may be due to homozygosity at the locus but chances are very rare (Capon et al., 1996) . In our population, we observed 9% of homozygosity in normal chromosome as compared to 73% in type I patient. Therefore, we believe that allelic reduction just as C212 in type I patient may also be due to deletion rather than homozygosity of the marker. In comparison with high rate of allelic loss in type I SMA, the allelic loss in type II (20% ) and III (16% ) SMA is low. Higher percentage of loss of alleles associated with SMN suggests that type I SMA patients may not produce even a partially functional SMN protein. However, type II/III and IV patients may produce some amount of functional protein, which may lead to milder phenotype .
SMN protein interacts directly or indirectly with other proteins, including Bcl-2 and p53, the proteins involved in apoptotic processes, suggesting that SMN may play a role in apoptosis (Iwahashi et al., 1997; Young et al., 2002) . NAIP has been mapped in close proximity to the SMN gene and shows homology with the baculoviral IAPs (Inhibitor of apoptosis protein family), which functions as an inhibitor of apoptosis (Mclean et al., 1996) . This characteristic is wholly compatible with the pathology of SMA.
In our Indian patients only 28% of the patients with proximal SMA were found to have deletion of NAIP gene. In type I SMA higher percentage (41%) of NAIP deletion has been observed as compared with type II and III SMA (Table 1) . NAIP gene deletion frequencies in our patients are in concordance with the reported frequency from other populations (Rodrigues et al., 1995; Roy et al., 1995; Velsco et al., 1996) . From the data, it is clear that NAIP deleted individuals are a subset of those who also have the SMN1 gene deletion. NAIP gene deletion was not present in all type I patients and neither was it absent in all types II and III patients, as 14 and 26% of type II and III patients had deletion of NAIP gene but disease severity was not changed. NAIP was not deleted in many of type I patients despite a severe course and early onset of disease. Our data thus substantiates the view that majority of type I SMA cases result from large deletions encompassing both SMN and NAIP gene but it dose not support the direct role of NAIP in disease severity. Taylor et al. (1998) have shown that small mutation within the SMN1 gene do not disrupt NAIP but may still give rise to severe phenotype. These results suggest that NAIP may not have a direct role in SMA severity but simply delimit the extent of deletions within the SMA region . We agree with other studies (Campbell et al., 1997) that NAIP may be coincidentally deleted with SMN gene.
In our study, type I patients showed large deletions, encompassing genomic regions upstream and downstream of the SMN gene. Large deletion in 5q13 region have been found to be associated with type I SMA, as 41% of patients showed a loss of alleles detected by markers C212 and C272 along with deletion of SMN1 and NAIP genes, whereas most of type II and III showed deletions of SMN1 only. This finding is in accordance with the observation that these types of defects are specific to the severe form of SMA (Wirth et al., 1995; Burlet et al., 1996) . Extended gene deletions were low in our patients having a milder phenotype. An individual who has SMA and is homozygous for both NAIP and SMN1 deletions is more likely to have type I SMA than type II or III SMA. Although extent of deletion apparently explains some of the phenotypic variation in SMA, there must be other disease modifying factors, as well in SMA pathogenesis.
SMN2 is another disease modifying gene for SMA and has been proposed to decrease severity of SMA in a dose dependent manner (McAndrew et al., 1997; Fedkotter et al., 2002) . To determine whether mild SMA patients have more SMN2 copies than severe patients, we performed a comparison of SMN2 copy number in SMA patients with different severities. Our results demonstrated that there are more copies of SMN2 in mild SMA patients compared with severe cases. Interestingly, 67% of type III patients had 4 copies of SMN2 and 1 patient had 5 copies and 1 had 3 copies of SMN2 gene. No type III patients were identified with 1 or 2 copies of SMN2 gene. These data indicate that the presence of three or more copies of SMN2 is clearly correlated with milder phenotype. The increase in copy numbers of SMN2 may correspond to conversion of SMN1 to SMN2 gene rather than deletions of SMN1 gene in these patients. However, the number of affected individuals of known SMA type in our study was small due to the limitation of sample for quantitative PCR. Previous studies with larger numbers of subjects indicate that individuals with milder SMA have more copies of SMN2 than individuals with more severe SMA (Taylor et al., 1998; Mailman et al., 2002) .
Combined analyses of SMN1/SMN2, together with NAIP and markers C212/C272 revealed an association between the copy number of gene and the SMA phenotype Wirth et al., 1995; Velasco et al., 1996; Burglen et al., 1997) . As discussed earlier, type I SMA patients showed a large deletion at 5q locus. In type II and III patients, extended gene deletions were low. These observations favour two different mechanisms that would account for the lack of SMN1 gene in SMA patients: a gene deletion of SMN1 in type I SMA and a gene conversion (SMN1 to SMN2) event in type II/III SMA Wirth et al., 1995; Velasco et al., 1996; Campbell et al., 1997; McAndrew et al., 1997) . Therefore, in the majority of cases an increased number of SMN2 copies correlates with milder SMA phenotype. It also suggests that the SMN2 gene is translated into an at least partially functional protein and could be regarded as a true modifying gene in SMA.
In conclusion, it is tempting to state that extent of deletions encompassing H4F5, SMN1, and NAIP along with copy number of SMN2 may modify the SMA phenotype, thus accounting for the different clinical subtypes of the disease. Molecular dissection of SMN locus will further aid in elucidating the phenotypic variability in SMA.
